RTGF(SZ:002440)2021-04-29 16:00Financial Performance - The company's operating revenue for Q1 2021 was ¥1,416,761,800.01, representing a 23.92% increase compared to ¥1,143,295,829.45 in the same period last year[10] - Net profit attributable to shareholders was ¥176,455,249.39, a decrease of 23.40% from ¥230,368,577.42 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥131,611,719.49, showing a significant increase of 133.44% compared to ¥56,378,882.31 in the previous year[10] - Basic earnings per share decreased by 25.00% to ¥0.15 from ¥0.20 year-on-year[10] - The company reported a net profit of approximately ¥6.39 billion in retained earnings, an increase from ¥6.21 billion[59] - Total operating revenue for the current period reached ¥1,416,761,800.01, an increase of 23.9% compared to ¥1,143,295,829.45 in the previous period[68] - Net profit for the current period was ¥171,491,445.85, a decrease of 23.2% from ¥223,008,268.00 in the previous period[74] - The total comprehensive income attributable to the parent company is CNY 177,591,773.64, compared to CNY 230,938,419.07 in the previous period, reflecting a decrease of 23.1%[77] Cash Flow and Liquidity - The net cash flow from operating activities was ¥57,752,462.09, down 88.90% from ¥520,197,091.61 in the same period last year[10] - The company’s cash outflow from operating activities increased by 94.22% to 985,494,855.09 from 507,422,001.00 primarily due to higher cash payments for raw materials and taxes[26] - Cash and cash equivalents decreased by 30.46% to 1,435,741,579.44 from 2,064,637,158.63 due to repayment of short-term bank loans[23] - The company reported a net decrease in cash and cash equivalents of -586,642,305.09, contrasting with an increase of 310,351,180.14 in the previous period[96] - The ending balance of cash and cash equivalents was 1,016,475,953.39, an increase from 542,112,971.97 in the previous period[96] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,018,881,069.67, a decrease of 2.95% from ¥11,354,172,670.91 at the end of the previous year[10] - Total liabilities decreased significantly with short-term borrowings dropping to 0.00 from 370,302,222.22, reflecting repayment of bank loans[23] - Current liabilities decreased to approximately ¥1.31 billion, down by 24.87% from ¥1.75 billion[56] - Total liabilities decreased to ¥1,183,151,428.74 from ¥1,275,747,352.78, a decline of about 7.3%[66] - The total equity attributable to shareholders increased to approximately ¥9.26 billion, up by 1.15% from ¥9.15 billion[59] Research and Development - Research and development expenses rose by 68.39% to 40,284,044.94 from 23,922,990.38 as R&D investments returned to normal levels after a decrease due to COVID-19 impacts last year[23] - Research and development expenses rose to ¥40,284,044.94, compared to ¥23,922,990.38 in the previous period, marking an increase of 68.3%[71] - The company reported investment income of ¥22,536,657.28, up from ¥13,323,950.61, representing a growth of 69.0%[71] Shareholder Activities - The company repurchased a total of 12,750,000 shares, accounting for 1.1082% of the total share capital, with a total expenditure of approximately RMB 122.32 million[31] - The maximum transaction price during the share repurchase was RMB 9.95 per share, while the minimum was RMB 9.15 per share[31] - The company plans to use its own funds to repurchase shares for employee stock ownership plans, with a total repurchase fund not less than RMB 200 million and not exceeding RMB 400 million[31] Government and Regulatory - The company reported government subsidies of ¥53,099,847.01 during the reporting period[10] - The company reported a 192.13% increase in taxes and surcharges to 15,328,104.11 from 5,246,995.19 due to higher payable additional taxes compared to the same period last year[23] - There were no overdue amounts or uncollected funds from entrusted financial management during the reporting period[40] - There were no violations of external guarantees during the reporting period[43] - The company did not have any non-operating fund occupation by controlling shareholders or related parties during the reporting period[44] Investment Activities - The company has invested 3,800,000 RMB in a healthcare-focused venture capital fund through its wholly-owned subsidiary, indicating a strategic move into the healthcare sector[30] - The company’s major financial investments include RMB 68 million in bank wealth management products and RMB 3 million in securities firm wealth management products, totaling RMB 71 million[40]